A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

Study Summary

The BMN 270 clinical development program consists of multiple interventional studies designed to assess the safety and efficacy of a single infusion of BMN 270 for at least 5 years post-infusion. This long-term follow-up study is needed to help further understand the long-term safety of BMN 270 beyond 5 years and to assess the durability of efficacy.

Conditions

Hemophilia A

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

BMRN

BioMarin Pharmaceutical

Rare Disease

D36/100

Study Details

Enrollment172 participants

Primary Completion—

Lead SponsorBioMarin Pharmaceutical

Data Retrieved2026-04-11 02:55:23.531545+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.